Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30016217 | 1.00 | POLQ (0.50) | POLQSYK | |
| SCHEMBL30017442 | 0.89 | POLQ (0.52) | POLQ | |
| SCHEMBL31418459 | 0.89 | POLQ (0.52) | POLQ | |
| SCHEMBL24770187 | 0.89 | POLQ (0.52) | POLQ | |
| SCHEMBL24500651 | 0.88 | POLQ (0.54) | POLQ | |
| SCHEMBL29694934 | 0.88 | POLQ (0.54) | POLQ | |
| SCHEMBL25309974 | 0.81 | POLQ (0.46) | POLQ | |
| SCHEMBL30526727 | 0.81 | POLQ (0.46) | POLQ | |
| SCHEMBL25262459 | 0.81 | AKR1C3 (0.46) | POLQ | |
| SCHEMBL24501488 | 0.81 | POLQ (0.48) | POLQ |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4676480-A1 | INHIBITORS OF DNA POLYMERASE THETA | Breakpoint Therapeutics GmbH (DE) | 2026-01-14 | — | — | EP | disclosed |
| US-20250122221-A1 | SIX-MEMBERED CYCLOTHIAZOLE COMPOUND AND USE THEREOF | NANJING ZAIMING PHARMACEUTICAL CO., LTD. (CN) | 2025-04-17 | — | — | US | disclosed |
| WO-2025016391-A1 | THIAZOLE PYRAZINE COMPOUNDS AND USE THEREOF | 南京再明医药有限公司 | 2025-01-23 | — | — | WO | disclosed |
| EP-4464709-A1 | SIX-MEMBERED CYCLOTHIAZOLE COMPOUND AND USE THEREOF | Nanjing Zaiming Pharmaceutical Co., Ltd. (CN) | 2024-11-20 | — | — | EP | disclosed |
| WO-2024189493-A1 | INHIBITORS OF DNA POLYMERASE THETA | BREAKPOINT THERAPEUTICS GMBH (DE) | 2024-09-19 | — | — | WO | disclosed |
| WO-2023134739-A1 | SIX-MEMBERED CYCLOTHIAZOLE COMPOUND AND USE THEREOF | 南京再明医药有限公司 | 2023-07-20 | — | — | WO | disclosed |
| WO-2022259204-A1 | O-LINKED THIADIAZOLYL COMPOUNDS AS DNA POLYMERASE THETA INHIBITORS | IDEAYA BIOSCIENCES, INC. (US) | 2022-12-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250122221-A1 | SIX-MEMBERED CYCLOTHIAZOLE COMPOUND AND USE THEREOF | POLRMT, POLQ, POLH | POLQ 2/4885SYK 1402/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.